Medical/Pharmaceuticals

111 to Announce Third Quarter 2021 Unaudited Financial Results on November 19, 2021 - Conference Call to Follow

SHANGHAI, Oct. 28, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...

2021-11-02 04:57 2004

SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8

New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven ...

2021-11-01 20:03 1714

Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic

JIUQUAN, China, Nov. 1, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that recently, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), the Comp...

2021-11-01 20:00 1227

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments

SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment ofJohn Long as the Company's Chief Finan...

2021-11-01 20:00 1306

MGI Unveils Performance Upgrades for its Sequencing Platforms* and Customized ATOPlex Platform at the 16th International Conference on Genomics

QINGDAO, China, Nov. 1, 2021 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, introduced a series of performance upgrades for its gene sequencing platforms* and a new multiplex PCR platform at the 16th International Conference on Genomics (ICG-16) held inQingd...

2021-11-01 19:52 1518

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia

GAITHERSBURG, Md. and PUNE, India, Nov. 1, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine ma...

2021-11-01 18:57 2691

Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study

* U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study * The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, A...

2021-11-01 18:00 2050

WuXi Biologics Launches a New GMP Commercial Drug Product Facility

* Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production * Increases up to 60 million vials for commercial drug production per year * Consolidates WuXi Biologics' pioneering the application of innovative technologies such as si...

2021-11-01 10:19 3518

Suzhou Ribo Life Science Co. Ltd. Adopts ArisGlobal's LifeSphere® MultiVigilance to Advance Data Management from Clinical Trials

Innovative R&D company selects LifeSphere by ArisGlobal to further develop its safety capabilities MIAMI, Nov. 1, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphe...

2021-11-01 09:00 2684

Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

SHANGHAI and HONG KONG, Nov. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-11-01 08:40 2475

Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH

SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC43F, a first-...

2021-11-01 08:30 2168

Farrer Park Hospital Introduced Actinium-225 PSMA Nuclear Therapy for Advanced Prostate Cancer

Earlier trials using Actinium-225 PSMA showed an improved biochemical response and better cancer-killing effects as Actinium-225 PSMA uses a much more potent radioactive ligand. SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- Prostate cancer is the 3rd most common cancer among Singaporean men. Every day...

2021-11-01 08:15 1780

HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients

CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 /PRNewswire/ -- After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current sh...

2021-11-01 08:00 968

Everest Medicines Announces Share Repurchase Transaction Details

SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that it ...

2021-11-01 08:00 1893

Invetech Named Victorian Top Exporter of the Year

MELBOURNE, Australia, Oct. 30, 2021 /PRNewswire/ -- Invetech, an end-to-end commercialisation partner to world's foremost therapeutic and diagnostic companies, has been named the Victorian Exporter of the Year at the2021 Governor of Victoria Export Awards (GOVEA). Invetech also won the Internatio...

2021-10-30 05:35 3188

Award-winning abstracts confirm benefits of Elekta Unity in precision radiation therapy

CHICAGO, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of new award-winning abstracts supporting the many benefits of Elekta Unity in treating cancer patients using precision radiation therapy. The abstracts add to the growing body of data manifesting Elekta Un...

2021-10-29 22:15 3024

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

-- Application marks the first protein-based COVID-19 vaccine submitted to regulatory authorities for provisional approval inAustralia  -- In addition to today's submission to the Therapeutic Goods Administration, the company recently filed for authorization with MHRA, with additional filings in...

2021-10-29 19:15 5674

Baylor and Harvard Researchers Partner in Long-Term, Global Study of Human Flourishing

Researchers at Harvard University and Baylor University launch the largest initiative of its kind to investigate the determinants of human flourishing. "The Global Flourishing Study" is a $43.4 million, five-year annual study of 240,000 individuals in 22 countries across a broad range of well-bei...

2021-10-29 19:00 2670

China's New Regulation on Internet Healthcare will Benefit Platforms like WeDoctor

HANGZHOU, China, Oct. 29, 2021 /PRNewswire/ -- On 27 October, China's National Health Commission (NHC), the authority responsible for the medical industry, issued a new policy that calls for the regulation ofChina's fast-growing Internet healthcare industry. The policy is expected to pushChina's ...

2021-10-29 17:41 1161

Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%

SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...

2021-10-29 17:17 1248
1 ... 326327328329330331332 ... 578

Week's Top Stories